PNX
3,7-DIMETHYL-1-(5-OXOHEXYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
Created: | 2005-06-28 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 38 |
Chiral Atom Count | 0 |
Bond Count | 39 |
Aromatic Bond Count | 10 |
Chemical Component Summary | |
---|---|
Name | 3,7-DIMETHYL-1-(5-OXOHEXYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE |
Synonyms | PENTOXIFYLLINE |
Systematic Name (OpenEye OEToolkits) | 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione |
Formula | C13 H18 N4 O3 |
Molecular Weight | 278.307 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C2N(c1ncn(c1C(=O)N2CCCCC(=O)C)C)C |
SMILES | CACTVS | 3.341 | Cn1cnc2N(C)C(=O)N(CCCCC(C)=O)C(=O)c12 |
SMILES | OpenEye OEToolkits | 1.5.0 | CC(=O)CCCCN1C(=O)c2c(ncn2C)N(C1=O)C |
Canonical SMILES | CACTVS | 3.341 | Cn1cnc2N(C)C(=O)N(CCCCC(C)=O)C(=O)c12 |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | CC(=O)CCCCN1C(=O)c2c(ncn2C)N(C1=O)C |
InChI | InChI | 1.03 | InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 |
InChIKey | InChI | 1.03 | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB00806 |
---|---|
Name | Pentoxifylline |
Groups |
|
Description | Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties.[A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for its possible use in diverse conditions, including osteoradionecrosis, diabetic kidney disease, and generally any condition associated with fibrosis.[A226410, A226415, A226455] More recently, PTX has been suggested as a possible treatment for COVID-19-induced pulmonary complications due to its ability to regulate the production of inflammatory cytokines.[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but have since been discontinued. A branded product, PENTOXIL, marketed by Upsher-Smith Laboratories, and generic forms marketed by Valeant Pharmaceuticals and APOTEX have been available since the late 1990s.[L30300] |
Synonyms |
|
Brand Names |
|
Indication | Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.[L30300] |
Categories |
|
ATC-Code |
|
CAS number | 6493-05-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Adenosine receptor A2a | MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA... | unknown | agonist |
Tumor necrosis factor | MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCL... | unknown | other/unknown |
Phosphodiesterase enzymes | - | unknown | inhibitor |
5'-nucleotidase | MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSK... | unknown | inhibitor |
Adenosine receptor A1 | MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVS... | unknown | |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL628 |
PubChem | 4740 |
ChEMBL | CHEMBL628 |
ChEBI | CHEBI:7986 |
CCDC/CSD | JAKGEH, WEDXEL, WEDXIP, FEFYIA, JAKGEH01, HUNJEH, DUKJUR, FEFYAS, HUNJIL, HUNJOR, FEFYEW, IXUCEM |
COD | 7228842, 7228844, 2232472 |